FATE THERAPEUTICS INC Operating Cash Flow
FATE THERAPEUTICS INC (FATE) reported Operating Cash Flow of -$23.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$23.40M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$30.82M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$23.31M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$24.37M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2025 was -$106.08M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2024 was -$122.87M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2023 was -$132.26M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2022 was -$248.21M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$23.40M 10-Q · filed 2026-08-13 | -$54.26M 10-Q · filed 2026-08-13 | -$77.54M derived: sum of 3 quarters · filed 2026-08-13 | -$101.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$30.82M 10-Q · filed 2026-05-13 | -$54.14M derived: sum of 2 quarters · filed 2026-05-13 | -$78.51M derived: sum of 3 quarters · filed 2026-05-13 | -$103.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$23.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$47.69M derived: sum of 2 quarters · filed 2026-02-26 | -$72.28M derived: sum of 3 quarters · filed 2026-08-13 | -$106.08M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$24.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$48.96M derived: sum of 2 quarters · filed 2026-08-13 | -$82.77M 10-Q · filed 2025-11-13 | -$110.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$24.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$58.40M 10-Q · filed 2026-08-13 | -$86.19M derived: sum of 3 quarters · filed 2026-08-13 | -$115.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$33.81M 10-Q · filed 2026-05-13 | -$61.61M derived: sum of 2 quarters · filed 2026-05-13 | -$91.03M derived: sum of 3 quarters · filed 2026-05-13 | -$123.33M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$27.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$57.22M derived: sum of 2 quarters · filed 2026-02-26 | -$89.52M derived: sum of 3 quarters · filed 2026-02-26 | -$122.87M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$29.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$61.73M derived: sum of 2 quarters · filed 2025-11-13 | -$95.08M 10-Q · filed 2025-11-13 | -$131.71M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$32.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$65.66M 10-Q · filed 2025-08-12 | -$102.29M derived: sum of 3 quarters · filed 2025-08-12 | -$140.57M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$33.35M 10-Q · filed 2025-05-13 | -$69.99M derived: sum of 2 quarters · filed 2025-05-13 | -$108.26M derived: sum of 3 quarters · filed 2025-05-13 | -$136.75M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$36.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$74.91M derived: sum of 2 quarters · filed 2025-03-05 | -$103.40M derived: sum of 3 quarters · filed 2025-03-05 | -$132.26M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$38.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$66.77M derived: sum of 2 quarters · filed 2024-11-12 | -$95.63M 10-Q · filed 2024-11-12 | -$171.01M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$28.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$57.35M 10-Q · filed 2024-08-13 | -$132.74M derived: sum of 3 quarters · filed 2024-08-13 | -$187.79M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$28.86M 10-Q · filed 2024-05-09 | -$104.25M derived: sum of 2 quarters · filed 2024-05-09 | -$159.30M derived: sum of 3 quarters · filed 2024-05-09 | -$212.46M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$75.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$130.44M derived: sum of 2 quarters · filed 2024-02-26 | -$183.59M derived: sum of 3 quarters · filed 2024-02-26 | -$248.21M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$55.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$108.21M derived: sum of 2 quarters · filed 2023-11-08 | -$172.82M 10-Q · filed 2023-11-08 | -$243.11M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$53.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$117.77M 10-Q · filed 2023-08-08 | -$188.06M derived: sum of 3 quarters · filed 2023-08-08 | -$221.44M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$64.61M 10-Q · filed 2023-05-03 | -$134.91M derived: sum of 2 quarters · filed 2023-05-03 | -$168.28M derived: sum of 3 quarters · filed 2023-05-03 | -$200.39M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | -$70.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$103.67M derived: sum of 2 quarters · filed 2023-02-28 | -$135.77M derived: sum of 3 quarters · filed 2023-02-28 | -$162.87M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$33.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$65.48M derived: sum of 2 quarters · filed 2022-11-03 | -$92.58M 10-Q · filed 2022-11-03 | -$113.24M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$32.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$59.20M 10-Q · filed 2022-08-03 | -$79.87M derived: sum of 3 quarters · filed 2023-02-28 | -$110.60M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$27.10M 10-Q · filed 2022-05-04 | -$47.76M derived: sum of 2 quarters · filed 2023-02-28 | -$78.49M derived: sum of 3 quarters · filed 2023-02-28 | -$39.65M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$20.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$51.40M derived: sum of 2 quarters · filed 2023-02-28 | -$12.56M derived: sum of 3 quarters · filed 2023-02-28 | -$39.23M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$30.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $8.11M derived: sum of 2 quarters · filed 2021-11-04 | -$18.57M 10-Q · filed 2021-11-04 | -$44.10M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $38.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $12.17M 10-Q · filed 2021-08-04 | -$13.37M derived: sum of 3 quarters · filed 2022-02-28 | -$33.20M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$26.67M 10-Q · filed 2021-05-05 | -$52.21M derived: sum of 2 quarters · filed 2022-02-28 | -$72.05M derived: sum of 3 quarters · filed 2022-02-28 | -$92.36M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$25.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$45.37M derived: sum of 2 quarters · filed 2022-02-28 | -$65.68M derived: sum of 3 quarters · filed 2022-02-28 | -$83.17M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$19.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$40.15M derived: sum of 2 quarters · filed 2020-11-05 | -$57.64M 10-Q · filed 2020-11-05 | -$68.66M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$20.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$37.80M 10-Q · filed 2020-08-05 | -$48.82M derived: sum of 3 quarters · filed 2021-02-24 | -$52.38M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$17.49M 10-Q · filed 2020-05-11 | -$28.51M derived: sum of 2 quarters · filed 2021-02-24 | -$32.07M derived: sum of 3 quarters · filed 2021-02-24 | -$43.59M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | -$11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$14.58M derived: sum of 2 quarters · filed 2021-02-24 | -$26.10M derived: sum of 3 quarters · filed 2021-02-24 | -$38.65M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$3.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$15.08M derived: sum of 2 quarters · filed 2019-11-05 | -$27.63M 10-Q · filed 2019-11-05 | -$38.35M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$11.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$24.07M 10-Q · filed 2019-08-06 | -$34.80M derived: sum of 3 quarters · filed 2020-03-02 | -$44.56M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$12.55M 10-Q · filed 2019-05-07 | -$23.27M derived: sum of 2 quarters · filed 2020-03-02 | -$33.04M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$20.49M derived: sum of 2 quarters · filed 2020-03-02 | -$36.82M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$9.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$26.10M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | -$16.33M 10-Q · filed 2018-08-06 | |||
| 2016-12-31 | -$29.82M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |